# Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

> **NCT00080886** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 68 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** carmustine
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** melphalan
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00080886
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05-08
- **Primary completion:** 2005-11-01
- **Final completion:** 2015-03-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080886, "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00080886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*